Contact this trialFirst, we need to learn more about you.
HIF-2alpha Inhibitor
Belzutifan for Kidney Cancer
Recruiting1 awardPhase 1
Ann Arbor, Michigan
This trial is testing belzutifan, a medication for patients with advanced kidney cancer that hasn't responded to previous treatments. The drug works by blocking a protein that cancer cells need to grow. Researchers aim to find out if it is safe and effective for these patients. Belzutifan has received FDA approval for treating von Hippel-Lindau-associated renal cell carcinoma and has shown significant efficacy in related tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service